⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6647 | 1.00 | — | — | |
| SCHEMBL65076 | 1.00 | — | — | |
| SCHEMBL28953280 | 1.00 | LMNA (0.57) | — | |
| SCHEMBL28669794 | 0.96 | — | — | |
| Glycerin SCHEMBL5132960 | 0.96 | LMNA (0.64) | — | |
| Methane SCHEMBL28164214 | 0.96 | — | — | |
| SCHEMBL31258069 | 0.96 | — | — | |
| Ammonia Solution, Strong SCHEMBL3183119 | 0.96 | — | — | |
| Water SCHEMBL18941413 | 0.96 | — | — | |
| Hydrochloric Acid SCHEMBL27991069 | 0.96 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059813-B2 | Polymorphic forms of Dasatinib | BIOCON LIMITED (IN) | 2021-07-13 | — | — | US | claimed |
| US-20200377495-A1 | POLYMORPHIC FORMS OF DASATINIB | BIOCON LIMITED (IN) | 2020-12-03 | — | — | US | claimed |
| EP-3649126-A1 | POLYMORPHIC FORMS OF DASATINIB | Biocon Limited (IN) | 2020-05-13 | — | — | EP | claimed |
| CN-111108104-A | Polymorphic forms of dasatinib | 拜康有限公司 | 2020-05-05 | — | — | CN | claimed |
| WO-2019008555-A1 | POLYMORPHIC FORMS OF DASATINIB | BIOCON LIMITED (IN) | 2019-01-10 | — | — | WO | claimed |
| CN-107880013-A | A kind of synthetic method of five-membered ring list sulfocarbonate | 常熟理工学院 | 2018-04-06 | — | — | CN | claimed |
| WO-2017221211-A1 | PROCESS FOR THE PREPARATION OF DAPAGLIFLOZIN AND ITS SOLVATE THEREOF | BIOCON LIMITED (IN) | 2017-12-28 | — | — | WO | claimed |
| US-9845303-B2 | Process for the preparation of dapagliflozin | CADILA HEALTHCARE LIMITED (IN) | 2017-12-19 | — | — | US | claimed |
| US-20170166547-A1 | PROCESS FOR THE PREPARATION OF DAPAGLIFLOZIN | CADILA HEALTHCARE LIMITED (IN) | 2017-06-15 | — | — | US | claimed |
| EP-0317998-B1 | Manufacturing method of optically-active 1,2-diols | KANEGAFUCHI CHEMICAL IND (JP) | 1994-08-31 | — | — | EP | claimed |
| CN-122055373-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20250120989-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-04-17 | — | — | US | disclosed |
| WO-2025080879-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | VERNALIS (R&D) LTD (GB) | 2024-05-09 | — | — | US | disclosed |
| CN-111419830-B | Phenylalkylcarbamate compounds for use in the prevention or treatment of epilepsy and epileptic related syndromes | 比皮艾思药物研发有限公司 | 2024-01-30 | — | — | CN | disclosed |
| EP-0317998-B1 | Manufacturing method of optically-active 1,2-diols | KANEGAFUCHI CHEMICAL IND (JP) | 1994-08-31 | — | — | EP | disclosed |
| US-4981796-A | BIOSYNTHESIS | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1991-01-01 | — | — | US | disclosed |
| EP-0317998-A2 | Manufacturing method of optically-active 1,2-diols | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1989-05-31 | — | — | EP | disclosed |
| US-3944674-A | Combating insects with o dimethoxymethylphenyl-N-methylcarbamate | CIBA-GEIGY AG (CH) | 1976-03-16 | — | — | US | disclosed |
| US-3933858-A | INSECTICIDES | CIBA-GEIGY AG (CH) | 1976-01-20 | — | — | US | disclosed |